BioTuesdays

WB starts Phreesia at OP

William Blair launched coverage of Phreesia (NYSE:PHR) with an “outperform” rating. The stock closed at $27.37 on Aug. 9.

Phreesia, which went public in July 2019, gives healthcare organizations a suite of robust applications to manage the patient intake process.

Analyst Ryan Daniels writes that he projects the company’s fiscal 2020 EBITDA to be $2.5-million on revenue of $116.9-million. For fiscal 2021, he estimates EDBITDA of $6.4-million on revenue of $139.4-million.

Mr. Daniels noted six primary reasons to view Phreesia as a core small-cap healthcare IT holding:

  • Phreesia is well positioned to benefit from key mega trends in the healthcare marketplace.
  • Phreesia’s solutions address a critical but largely unmet need in the market, presenting ample organic growth opportunities.
  • Phreesia has a compelling end-to-end product suite, which provides high value to customers (both patients and providers) and also creates competitive advantages over industry peers.
  • Phreesia has a deep and experienced management team and innovative corporate culture.
  • High customer-retention rates and a largely recurring-revenue base create a solid financial model, with strong incremental margin opportunities.
  • And inorganic growth opportunities also could bolster the longer-term margin and growth profile of the company.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.